Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.31
- Piotroski Score 3.00
- Grade Neutral
- Symbol (CERE)
- Company Cerevel Therapeutics Holdings, Inc.
- Price $44.96
- Changes Percentage (0.74%)
- Change $0.33
- Day Low $44.96
- Day High $44.99
- Year High $44.99
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $33.50
- High Stock Price Target $40.00
- Low Stock Price Target $27.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.73
- Trailing P/E Ratio -14.66
- Forward P/E Ratio -14.66
- P/E Growth -14.66
- Net Income $-432,842,000
Income Statement
Quarterly
Annual
Latest News of CERE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
A Dodgers fan kept a Fernando Valenzuela-signed cereal box for 40 years. He brought it to the parade
Vincent Rodriguez proudly displayed his signed Kellogg's Corn Flakes box by Dodger legend Fernando Valenzuela at the World Series parade, a memento he cherished for over 40 years....
By CBS News | 2 days ago -
Excitement builds for 2024 TCS New York City Marathon at opening ceremony
Thousands of runners are gearing up for the 2024 TCS New York City Marathon, a challenging 26.2 mile race through the city's streets. Participants from around the world are ready to showcase their det...
By CBS News | 3 days ago -
Dodgers Stadium welcomes players as Ice Cube kicks off special ceremony
Ice Cube is leading the ceremony at Dodgers Stadium to honor the World Series champions. The sold-out event includes a surprise musical performance. Fans await the team's arrival after a downtown para...
By CBS News | 3 days ago
